NHSE Interim treatment options

Message from Steve Williamson, NHS England Lead Cancer Pharmacist

29th April 2020 – NHSE Interim treatment options

 

Dear Colleague

You may have seen that NICE has published an updated table to the SACT clinical guideline NG161 listing many new Interim treatment options earlier this week. See https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381. There are a couple of points of clarification for providers to note:

  • Enzalutamide for prostate cancer states it is subject to confirmation, we can confirm enzalutamide is approved, and there is no need to check for confirmation. A Blueteq form for abiraterone for patients unable to tolerate enzalutamide will be made available in due course.
  • Gilteritinib is approved for relapsed /refractory AML and not newly diagnosed AML.
  • Nivolumab is approved in MSI-H colorectal cancer, the wording states ‘subject to confirmation’ we can confirm this is approved and there is no need to check for confirmation.
  • A blueteq form for polatuzumab will be released in due course as NHSE is currently working with the company to ensure there is stock available for the selected patient group.

We advise all these indications are to be billed through the usual specialised commissioning route, as there is additional COVID19 funding available for them.  Any drugs where we have changed the CDF pathway are not funded through CDF as there is separate COVID19 funding for them. We are pleased to note that the manufacturers of many of these drugs have worked with NHS England and offered additional discounts to support the NHS during COVID19.

Latest News

By BOPA committee on 10th July 2025

Update to BOPA Standards – New Guidance on Pharmacy Technician SACT Verification (Section 3.3)

Dear BOPA Members, We are pleased to share an important update to the BOPA Standards for the Pharmacy Verification of Prescriptions for Cancer Medicines (Version 5.0, 3 June 2025). A…

Read article
By Joseph Williams on 4th July 2025

Pharmacists’ Essential Guide to Haematology Course – 15th–16th September 2025 at UCLH

We’re excited to announce the next Pharmacists’ Essential Guide to Haematology course, hosted by the UCLH Cancer Academy. This two-day course is designed specifically for pharmacists starting their haem-oncology journey,…

Read article
By BOPA Research committee on 26th June 2025

SURVEY deadline extended – The use and development of ChemoCare Electronic Prescribing System for systemic anti-cancer therapy

Dear Oncology/Haematology Pharmacist, You are invited to participate in a survey exploring the factors that influence UK-registered pharmacists’ use and the development of ChemoCare Electronic Prescribing system (EPS) for systemic…

Read article
By BOPA Committee on 26th June 2025

“Cancer Basics” videos by Elaine Vickers available free on Youtube

Elaine Vickers, PhD, creator of the UTIC course, has also produced a playlist of ten short videos on “Cancer Basics”, which is freely available on YouTube. In these videos, Elaine…

Read article